Genflow Biosciences PLC Notice of Annual General Meeting (5685Z)
16 Mai 2023 - 10:50AM
UK Regulatory
TIDMGENF
RNS Number : 5685Z
Genflow Biosciences PLC
16 May 2023
16 May 2023
Genflow Biosciences Plc
("Genflow" or "the Company")
Notice of Annual General Meeting
Genflow (LSE: GENF), a UK-based biotechnology company focused on
longevity and the development of therapies to counteract the
effects of aging and diseases associated with advanced age, is
pleased to announce that it will hold its Annual General Meeting
("AGM") at 09:00am on Thursday 8 June 2023 at the offices of
Westend Corporate LLP, 6 Heddon Street, London, W1B 4BT.
The Notice of the AGM ("Notice") and 2023 Form of Proxy are now
available on the Company's website, www.genflowbio.com , and have,
where applicable, been posted to shareholders. Further details of
the arrangements for this year's AGM are set out in the Notice.
As announced on 24 April 2023, the Company's Annual Report and
Accounts for the year ended 31 December 2022 is also available on
the website and has, where applicable, also been posted to
registered shareholders.
For further information please contact:
Genflow Biosciences Plc
Dr Eric Leire
Chief Executive +32 477 495 881
-----------------
Clear Capital Markets Ltd
-----------------
Corporate Broker
Andrew Blaylock +44 203 869 6080
-----------------
About Genflow
Genflow is a UK-based biotechnology company established in 2020.
The Company is developing gene therapies designed to target the
aging process and to reduce and delay the incidence of age-related
diseases. This will be done through novel therapeutics targeting
aging in humans by using adeno-associated virus ("AAV") vectors to
deliver copies of the Sirtuin-6 ("SIRT6") gene variant that is
found in centenarians into cells.
Its mission is to increase our understanding of the factors that
control and impact lifespan. Genflow researches, develops, and
commercialises therapeutic solutions to lengthen health span, the
amount of time we live in good health, creating biological
interventions that enable longer and healthier lives. Genflow is
dedicated to the development and commercialisation of novel
therapeutics targeting aging in dogs and humans. By treating aging,
Genflow can contribute to a decrease in healthcare costs and lessen
the emotional and societal burden that comes with an aging
population.
To learn more visit www.genflowbio.com
-Ends-
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAUNSWROWUVARR
(END) Dow Jones Newswires
May 16, 2023 04:50 ET (08:50 GMT)
Genflow Biosciences (LSE:GENF)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Genflow Biosciences (LSE:GENF)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024